1. Home
  2. IREN vs HALO Comparison

IREN vs HALO Comparison

Compare IREN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iris Energy Limited

IREN

Iris Energy Limited

BUY

Current Price

$25.17

Market Cap

12.0B

Sector

Technology

ML Signal

BUY

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$124.21

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IREN
HALO
Founded
2018
1998
Country
Australia
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
12.0B
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
IREN
HALO
Price
$25.17
$124.21
Analyst Decision
Buy
Buy
Analyst Count
20
9
Target Price
$77.81
★ $108.78
AVG Volume (30 Days)
★ 39.3M
2.1M
Earning Date
11-05-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ 3.11
Revenue
★ $707,007,000.00
$151,862,000.00
Revenue This Year
$297.12
$34.69
Revenue Next Year
$163.96
$11.65
P/E Ratio
★ N/A
$40.28
Revenue Growth
★ 41.11
N/A
52 Week Low
$25.59
$61.23
52 Week High
$76.87
$125.43

Technical Indicators

Market Signals
Indicator
IREN
HALO
Relative Strength Index (RSI) 25.08 71.60
Support Level N/A $105.27
Resistance Level $44.21 N/A
Average True Range (ATR) 2.32 3.48
MACD -1.13 1.13
Stochastic Oscillator 2.31 93.48

Price Performance

Historical Comparison
IREN
HALO

About IREN Iris Energy Limited

IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: